Der Onkologe

, Volume 17, Issue 5, pp 377–383 | Cite as

Ganzkörperdiffusionsbildgebung in der Onkologie

Technische Aspekte und praktischer Stellenwert
Leitthema
First Online:
  • 49 Downloads

Zusammenfassung

Der vorliegende Beitrag erläutert auf Basis der aktuellen Literatur die Bedeutung der Ganzkörperdiffusionswichtung (GK-DW) im Umfeld der onkologischen Bildgebung. Die GK-DW stellt aufgrund der fehlenden Strahlenbelastung und der niedrigeren Kosten als Alternative zur PET/CT dar. Technische Aspekte der GK-DW sowie der gegenwärtige Stellenwert der Methode unter Berücksichtigung onkologischer Anforderungen werden vorgestellt.

Schlüsselwörter

Ganzkörperbildgebung Diffusionsbildgebung Positronenemissionstomographie/Computertomographie Strahlenbelastung Kosten 

Whole-body diffusion-weighted imaging in oncology

Technical aspects and practical relevance

Abstract

This review illustrates the relevance of whole-body diffusion-weighted imaging (WB-DWI) in the field of oncological imaging. WB-DWI is an alternative method to positron-emission tomography/computed tomography (PET/CT) due to the lack of radiation and lower examination costs. Technical aspects of WB-DWI and the current role of the method in cancer imaging regarding practical requirements in oncology are presented.

Keywords

Whole-body imaging Diffusion-weighted imaging Positron emission tomography/Computed tomography Radiation exposure Costs 
This is a preview of subscription content, log in to check access.

Notes

Interessenkonflikt

Die korrespondierende Autorin gibt an, dass kein Interessenkonflikt besteht.

Literatur

  1. 1.
    Antoch G, Vogt FM, Freudenberg LS et al (2003) Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 290:3199–206PubMedCrossRefGoogle Scholar
  2. 2.
    Brenner DJ, Hall EJ (2007) Computed tomography – an increasing source of radiation exposure. N Engl J Med 357:2277–2284PubMedCrossRefGoogle Scholar
  3. 3.
    Chen W, Jian W, Li HT et al (2010) Whole-body diffusion-weighted imaging vs. FDG-PET for the detection of non-small-cell lung cancer. How do they measure up? Magn Reson Imaging 28:613–620PubMedCrossRefGoogle Scholar
  4. 4.
    Delfaut EM, Beltran J, Johnson G et al (1999) Fat suppression in MR imaging: techniques and pitfalls. Radiographics 19:373–382PubMedGoogle Scholar
  5. 5.
    Hamstra DA, Rehemtulla A, Ross BD (2007) Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol 25:4104–4109PubMedCrossRefGoogle Scholar
  6. 6.
    Holzapfel K, Duetsch S, Fauser C et al (2009) Value of diffusion-weighted MR imaging in the differentiation between benign and malignant cervical lymph nodes. Eur J Radiol 72:381–387PubMedCrossRefGoogle Scholar
  7. 7.
    Kim SH, Lee JM, Hong SH et al (2009) Locally advanced rectal cancer: added value of diffusion-weighted MR imaging in the evaluation of tumor response to neoadjuvant chemo- and radiation therapy. Radiology 253:116–125PubMedCrossRefGoogle Scholar
  8. 8.
    King AD, Ahuja AT, Yeung DK et al (2007) Malignant cervical lymphadenopathy: diagnostic accuracy of diffusion-weighted MR imaging. Radiology 245:806–813PubMedCrossRefGoogle Scholar
  9. 9.
    Koh DM, Collins DJ (2007) Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 188:1622–1635PubMedCrossRefGoogle Scholar
  10. 10.
    Koh DM, Takahara T, Imai Y, Collins DJ (2007) Practical aspects of assessing tumors using clinical diffusion-weighted imaging in the body. Magn Reson Med Sci 6:211–224PubMedCrossRefGoogle Scholar
  11. 11.
    Kwee TC, Takahara T, Ochiai R et al (2009) Whole-body diffusion-weighted magnetic resonance imaging. Eur J Radiol 70:409–417PubMedCrossRefGoogle Scholar
  12. 12.
    Kwee TC, Takahara T, Ochiai R et al (2008) Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology. Eur Radiol 18:1937–1952PubMedCrossRefGoogle Scholar
  13. 13.
    Kwee TC, Takahara T, Vermoolen MA et al (2010) Whole-body diffusion-weighted imaging for staging malignant lymphoma in children. Pediatr Radiol 40:1592–1602; quiz 1720–1721PubMedCrossRefGoogle Scholar
  14. 14.
    Le Bihan D, Breton E, Lallemand D et al (1986) MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology 161:401–407Google Scholar
  15. 15.
    Li S, Sun F, Jin ZY et al (2007) Whole-body diffusion-weighted imaging: technical improvement and preliminary results. J Magn Reson Imaging 26:1139–1144PubMedCrossRefGoogle Scholar
  16. 16.
    Low RN, Gurney J (2007) Diffusion-weighted MRI (DWI) in the oncology patient: value of breathhold DWI compared to unenhanced and gadolinium-enhanced MRI. J Magn Reson Imaging 25:848–858PubMedCrossRefGoogle Scholar
  17. 17.
    Mori T, Nomori H, Ikeda K et al (2008) Diffusion-weighted magnetic resonance imaging for diagnosing malignant pulmonary nodules/masses: comparison with positron emission tomography. J Thorac Oncol 3:358–364PubMedCrossRefGoogle Scholar
  18. 18.
    Murtz P, Krautmacher C, Traber F et al (2007) Diffusion-weighted whole-body MR imaging with background body signal suppression: a feasibility study at 3.0 Tesla. Eur Radiol 17:3031–3037PubMedCrossRefGoogle Scholar
  19. 19.
    Ohno Y, Koyama H, Onishi Y et al (2008) Non-small cell lung cancer: whole-body MR examination for M-stage assessment – utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. Radiology 248:643–654PubMedCrossRefGoogle Scholar
  20. 20.
    Padhani AR, Liu G, Koh DM et al (2009) Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 11:102–125PubMedGoogle Scholar
  21. 21.
    Patterson DM, Padhani AR, Collins DJ (2008) Technology insight: water diffusion MRI – a potential new biomarker of response to cancer therapy. Nat Clin Pract Oncol 5:220–233PubMedCrossRefGoogle Scholar
  22. 22.
    Satoh S, Kitazume Y, Ohdama S et al (2008) Can malignant and benign pulmonary nodules be differentiated with diffusion-weighted MRI? AJR Am J Roentgenol 191:464–470PubMedCrossRefGoogle Scholar
  23. 23.
    Sharma U, Danishad KK, Seenu V, Jagannathan NR (2009) Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. NMR Biomed 22:104–113PubMedCrossRefGoogle Scholar
  24. 24.
    Takahara T, Imai Y, Yamashita T et al (2004) Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med 22:275–282PubMedGoogle Scholar
  25. 25.
    Takenaka D, Ohno Y, Matsumoto K et al (2009) Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy. J Magn Reson Imaging 30:298–308PubMedCrossRefGoogle Scholar
  26. 26.
    Thoeny HC, De Keyzer F (2007) Extracranial applications of diffusion-weighted magnetic resonance imaging. Eur Radiol 17:1385–1393PubMedCrossRefGoogle Scholar
  27. 27.
    Tsushima Y, Takano A, Taketomi-Takahashi A, Endo K (2007) Body diffusion-weighted MR imaging using high b-value for malignant tumor screening: usefulness and necessity of referring to T2-weighted images and creating fusion images. Acad Radiol 14:643–650PubMedCrossRefGoogle Scholar
  28. 28.
    Uto T, Takehara Y, Nakamura Y et al (2009) Higher sensitivity and specificity for diffusion-weighted imaging of malignant lung lesions without apparent diffusion coefficient quantification. Radiology 252:247–254PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.Institut für Diagnostische und Interventionelle Radiologie und NeuroradiologieUniversitätsklinikum EssenEssenDeutschland

Personalised recommendations